A detailed history of Samlyn Capital, LLC transactions in Natera, Inc. stock. As of the latest transaction made, Samlyn Capital, LLC holds 718,352 shares of NTRA stock, worth $120 Million. This represents 1.47% of its overall portfolio holdings.

Number of Shares
718,352
Previous 1,447,946 50.39%
Holding current value
$120 Million
Previous $157 Million 41.77%
% of portfolio
1.47%
Previous 2.79%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$97.75 - $129.67 $71.3 Million - $94.6 Million
-729,594 Reduced 50.39%
718,352 $91.3 Million
Q2 2024

Aug 14, 2024

SELL
$85.28 - $112.6 $45.8 Million - $60.4 Million
-536,633 Reduced 27.04%
1,447,946 $157 Million
Q1 2024

May 15, 2024

SELL
$59.21 - $92.9 $112 Million - $176 Million
-1,890,222 Reduced 48.78%
1,984,579 $182 Million
Q4 2023

Feb 14, 2024

SELL
$37.55 - $62.64 $19.7 Million - $32.9 Million
-525,425 Reduced 11.94%
3,874,801 $243 Million
Q3 2023

Nov 14, 2023

BUY
$43.4 - $62.52 $38.9 Million - $56 Million
895,686 Added 25.56%
4,400,226 $195 Million
Q2 2023

Aug 14, 2023

BUY
$47.08 - $55.16 $41.3 Million - $48.4 Million
877,319 Added 33.39%
3,504,540 $171 Million
Q1 2023

May 15, 2023

SELL
$36.57 - $58.29 $64.5 Million - $103 Million
-1,763,151 Reduced 40.16%
2,627,221 $146 Million
Q4 2022

Feb 14, 2023

BUY
$34.17 - $47.91 $72.2 Million - $101 Million
2,113,236 Added 92.8%
4,390,372 $176 Million
Q3 2022

Nov 14, 2022

BUY
$36.93 - $56.68 $24.2 Million - $37.1 Million
655,121 Added 40.39%
2,277,136 $99.8 Million
Q2 2022

Aug 15, 2022

BUY
$28.13 - $44.54 $32 Million - $50.6 Million
1,136,524 Added 234.1%
1,622,015 $57.5 Million
Q1 2022

May 16, 2022

BUY
$30.32 - $91.33 $14.7 Million - $44.3 Million
485,491 New
485,491 $19.8 Million

Others Institutions Holding NTRA

About Natera, Inc.


  • Ticker NTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 96,957,400
  • Market Cap $16.2B
  • Description
  • Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...
More about NTRA
Track This Portfolio

Track Samlyn Capital, LLC Portfolio

Follow Samlyn Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Samlyn Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Samlyn Capital, LLC with notifications on news.